Lisata Therapeutics to Advance AI-Discovered Opioid Use Disorder Therapeutic into Human Clinical Trials by Early 2026
Reuters
Jun 17, 2025
Lisata <a href="https://laohu8.com/S/LENZ">Therapeutics</a> to Advance AI-Discovered Opioid Use Disorder Therapeutic into Human Clinical Trials by Early 2026
Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company, has announced plans to advance a new therapeutic for opioid use disorder (OUD) into human clinical trials early in 2026. This initiative arises from a strategic alliance with GATC Health Corp., leveraging GATC's AI-powered Multiomics Advanced Technology® platform. The AI-discovered therapeutic, a non-opioid small molecule, has shown a significant reduction in fentanyl intake during preclinical studies in murine models. Lisata will lead the development efforts, contributing its expertise in drug development and regulatory processes. The upcoming Phase 1 human trials will aim to validate the therapeutic's efficacy and safety, marking a significant step in the collaboration's objective to accelerate and enhance the success rate of drug development. Results from these trials have not yet been presented and are anticipated following the commencement of the trials.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9469697-en) on June 17, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.